Pitkin L, Luangdilok S, Corbishley C, Wilson P O G, Dalton P, Bray D, Mady S, Williamson P, Odutoye T, Rhys Evans P, Syrigos K N, Nutting C M, Barbachano Y, Eccles S, Harrington K J
Thomas Tatum Head and Neck Unit, St George's Hospital, London, UK.
Br J Cancer. 2007 Sep 3;97(5):670-7. doi: 10.1038/sj.bjc.6603907. Epub 2007 Aug 7.
The aim of this study was to evaluate the expression of CC chemokine receptor 7 (CCR7) in squamous cell cancer of the tonsil with respect to patterns of spread, relapse-free, overall and disease-specific survival. Eighty-four patients with squamous cell cancer of the tonsil were identified. There was a male predominance of 3 : 1 and the median age at diagnosis was 53 (range 35-86) years. The median duration of follow-up was 33 (range 2-124) months. There was a significant association between CCR7 immunopositivity and synchronous cervical nodal metastasis in patients with tonsillar cancer (Spearman's correlation coefficient 0.564; P<0.001). Relapse-free (P=0.0175), overall (P=0.0136) and disease-specific (P=0.0062) survival rates were significantly lower in patients whose tumours expressed high levels of CCR7. On multivariate analysis, high-level CCR7 staining predicted relapse-free (hazard ratio 3.0, 95% confidence intervals 1.1-8.0, P=0.026) and disease-specific (hazard ratio 10.2, 95% confidence intervals 2.1-48.6, P=0.004) survival. Fifteen percent of patients with the highest level of tumour CCR7 immunopositivity relapsed with systemic metastases. These data demonstrated that CCR7 expression was associated with cervical nodal and systemic metastases from tonsillar cancers. High levels of CCR7 expression predicted a poor prognosis.
本研究旨在评估CC趋化因子受体7(CCR7)在扁桃体鳞状细胞癌中的表达情况,及其与扩散模式、无复发生存率、总生存率和疾病特异性生存率的关系。共纳入84例扁桃体鳞状细胞癌患者。男性占比3:1,诊断时的中位年龄为53岁(范围35 - 86岁)。中位随访时间为33个月(范围2 - 124个月)。扁桃体癌患者中,CCR7免疫阳性与同步性颈部淋巴结转移之间存在显著关联(Spearman相关系数0.564;P<0.001)。肿瘤表达高水平CCR7的患者,其无复发生存率(P = 0.0175)、总生存率(P = 0.0136)和疾病特异性生存率(P = 0.0062)显著较低。多因素分析显示,高水平CCR7染色可预测无复发生存率(风险比3.0,95%置信区间1.1 - 8.0,P = 0.026)和疾病特异性生存率(风险比10.2,95%置信区间2.1 - 48.6,P = 0.004)。肿瘤CCR7免疫阳性水平最高的患者中有15%出现全身转移复发。这些数据表明,CCR7表达与扁桃体癌的颈部淋巴结转移和全身转移相关。高水平的CCR7表达预示预后不良。